Our Focus

We are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Our pipeline is comprised of cell-based therapies for cancer and immune disorders. Our cellular immunotherapies are based on our novel ex vivo cell programming approach, which we apply to modulate the therapeutic function and direct the fate of hematopoietic cells.

immuno-focus1-FPO

Our Cells of Interest

t-cell
T cells play a central role in fighting cancer and infections. We are developing ProTmune™, a programmed cellular immunotherapy for the prevention of life threatening complications, such as acute GvHD and CMV infection, that often compromise patients undergoing allogenic hematopoietic cell transplantation (HCT). We also have a collaboration with Juno Therapeutics to improve the therapeutic function of engineered T cell therapies. Additionally, we are pioneering the development of “off-the-shelf” engineered T cell cancer immunotherapies using our induced pluripotent cell platform.
nk-cell

Natural Killer, or NK cells, are also involved in protecting against cancer and infections. We are developing a specialized sub-type of NK cells called “adaptive NKs”, which have been shown to exhibit cellular memory, persistence and enhanced anti-tumor properties. Fate is collaborating with investigators at the University of Minnesota to clinically translate our adaptive NK cell cancer immunotherapy candidate for solid tumors. Additionally, we are pioneering the development of “off-the-shelf” engineered NK cell cancer immunotherapies using our induced pluripotent cell platform.

hsc

Hematopoietic stem and progenitor cells (HSPCs), or CD34+ cells, possess the ability to self-renew and differentiate into all types of mature blood cells and have a multitude of therapeutic potential. Fate is developing a programmed CD34+ cell‑based immunotherapy that expresses supra‑physiological levels of certain immuno‑regulatory factors, including PD-L1, as a novel treatment for immune disorders. Fate is collaborating with Boston Children’s Hospital to evaluate our programmed CD34+ cell-based immunotherapy in various preclinical models of immune dysfunction.

MENU